Advisory Committee Reformers
This article was originally published in RPM Report
FDA's Advisory Committee Oversight & Management Staff is charged with developing policies and guidelines for the 30 expert panels across the agency. The staff has been busy developing four separate guidance documents that revamp the advisory committee system. Here are the principle players in that effort.
You may also be interested in...
FDA’s advisory committee process is a critical part of the new drug approval process. But the official record keeping of the committees is not: there is no real role for the “minutes” FDA publishes summarizing the panel deliberations.
FDA would be wise to prepare for a new round of active, emotive open public sessions after the impact of the public testimony at the Benlysta lupus drug review on November 16. It’s been a long-time since a public session has had such a direct impact on creating a pro-approval atmosphere at a committee meeting.
July 2010 may have been one of the busiest and most important months ever for the Food & Drug Administration's new drug regulatory group. Here are 10 themes to think about heading into the fall.